RxDoctor Payments Data

Kaoru Harada, MD

Allergy & Immunology · Norwalk, CTNPI 1215383864

Payments from drug & device makers

What this record shows

12 manufacturers reported payments, led by Allerderm Laboratories at 54.7% of the total. Reporting peaked in 2021 at $1,125 and has fallen 97.7% since, to $26 in 2025. That places this record below the midpoint for allergy & immunology clinicians in CT, where the typical reported total is $2,044.

$1,829in general payments, 2019–2025

Across 23 payments — averaging $79.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Allerderm Laboratories$1K
  • Novartis$169
  • Novo Nordisk$125
  • AstraZeneca$122
  • Optinose US, Inc.$111
  • GSK$90
  • plus $212 from 6 others

What the payments were for

  • Food & beverage$82945%
  • Education$1,00055%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,829 in reported general payments places this provider in the 45th percentile of 54 allergy & immunology providers in Connecticut.

See all allergy & immunology providers in Connecticut

Medicare billing

Part B allowed, 2024
$21,507
Medicare patients
85
Services billed
764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$15,419
Breo ElliptaFluticasone/Vilanterol20$8,807
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$4,985
Wixela InhubFluticasone Propion/Salmeterol12$1,308
Ipratropium Bromide23$590
Albuterol Sulfate HfaAlbuterol Sulfate25$557
Montelukast Sodium33$423
Fluticasone Propionate18$308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$90$29,21155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 54 allergy & immunology providers in Connecticut.

Other allergy & immunology in Norwalk

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →